Achillion Pharmaceuticals, Inc.(NASDAQ : ACHN)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|REGN||Regeneron Pharmaceuticals, Inc.||-0.58%||450.57||2.7%||$522.91m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.20%||212.55||1.9%||$515.41m|
|GILD||Gilead Sciences, Inc.||-2.21%||61.40||1.0%||$485.52m|
|BNGO||BioNano Genomics, Inc.||-2.89%||9.73||0.0%||$374.38m|
|ALXN||Alexion Pharmaceuticals, Inc.||-0.59%||152.75||2.0%||$371.25m|
|CRSP||CRISPR Therapeutics AG||-1.25%||125.69||0.6%||$292.02m|
|EXAS||EXACT Sciences Corp.||3.67%||136.12||18.4%||$252.07m|
At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system.